12:00 AM
 | 
Oct 11, 1999
 |  BC Week In Review  |  Company News  |  Deals

Corixa, LigoCyte Pharmaceuticals deal

The companies will develop therapeutic and vaccine products that target Candida albicans infections using LigoCyte's anti-Candida antibodies. CRX will purchase LigoCyte...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >